Eledon Updates Phase 2 BESTOW Trial Enrollment for Tegoprubart in Preventing Organ Rejection

Eledon Pharmaceuticals, Inc., based in Irvine, California, has recently made significant progress in its Phase 2 BESTOW trial focused on tegoprubart. This trial aims to prevent kidney transplant rejection. As of July 29, 2024, the company has successfully enrolled the 80th participant, marking two-thirds of their projected recruitment goal.

David-Alexandre C. Gros, M.D., the Chief Executive Officer of Eledon, expressed gratitude towards the participants and their clinical teams for their high level of interest, which facilitated this milestone. Gros emphasized the ongoing need for innovative solutions in kidney transplant rejection prevention and confirmed that the trial is on track to complete enrollment by the end of the year.

The BESTOW trial is a multicenter, two-arm, active comparator clinical study. It plans to enroll around 120 kidney transplant participants across various sites in the United States, Europe, and Latin America. This study aims to evaluate the safety, pharmacokinetics, and effectiveness of tegoprubart, an anti-CD40 ligand antibody. Tegoprubart will be compared to tacrolimus, a commonly used calcineurin inhibitor. The primary focus is to assess graft function at 12 months post-transplant, measured by estimated glomerular filtration rate (eGFR). Improved eGFR is linked to better long-term outcomes for patients and graft survival.

Eledon Pharmaceuticals is engaged in several clinical trials to explore the potential of tegoprubart in preventing organ rejection for kidney transplant recipients. These include the ongoing Phase 2 BESTOW trial (NCT05983770), a Phase 1b trial (NCT05027906), and a long-term safety and efficacy extension study (NCT06126380).

Eledon Pharmaceuticals is a clinical-stage biotechnology firm dedicated to developing immune-modulating therapies for severe health conditions. Tegoprubart, their leading investigational product, is an anti-CD40L antibody targeting the CD40 Ligand. This ligand plays a central role in both adaptive and innate immune cell activation, making it a promising target for immunomodulatory treatments that do not deplete lymphocytes. The company's efforts extend into preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS).

The headquarters of Eledon Pharmaceuticals is situated in Irvine, California. The company leverages extensive knowledge of anti-CD40 Ligand biology to advance its research and development initiatives. Their work is poised to make significant contributions to the field of transplantation and beyond.

This progress in the BESTOW trial underscores the potential of tegoprubart as a novel solution in preventing kidney transplant rejection. Eledon's ongoing efforts in clinical research highlight their commitment to addressing critical needs in the medical community, particularly in organ transplantation.